Back to top
more

United Therapeutics (UTHR)

(Delayed Data from NSDQ)

$581.69 USD

581.69
575,311

+15.99 (2.83%)

Updated Apr 8, 2026 04:00 PM ET

After-Market: $583.50 +1.81 (0.31%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (94 out of 243)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Brokerage Reports

Research for UTHR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

9 items in cart

View Cart/Checkout

United Therapeutics Corporation [UTHR]

Reports for Purchase

Showing records 561 - 580 ( 659 total )

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 561

06/02/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of June 2

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 562

05/27/2013

Industry Report

Pages: 5

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 563

05/19/2013

Industry Report

Pages: 5

LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of May 20

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 564

04/30/2013

Company Report

Pages: 8

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 565

04/25/2013

Company Report

Pages: 9

Q1 Financials Beat on Top Line And Double-Digit Growth Intact; 2013 Focus Remains On New Products And Growth; Reiterate OUTPERFORM & $91 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 566

04/18/2013

Company Report

Pages: 11

Q1 Preview: We Believe Consensus Is Achievable; In 2013, We See New Product Progress And Continued Sales Growth; Reiterate OUTPERFORM And $91 FV

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 567

04/01/2013

Industry Report

Pages: 30

Emerging Pharmaceuticals - April and Remaining 2013 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 568

03/25/2013

Daily Note

Pages: 7

We Presume It Is Back To The Original Plan

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 569

03/13/2013

Company Report

Pages: 8

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 570

03/04/2013

Industry Report

Pages: 32

Emerging Pharmaceuticals-March and Remaining 2013 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 571

02/26/2013

Company Report

Pages: 12

2012 Financials Beat And Double Digit Growth Intact. Near- Term Focus Remains On March 31st PDUFA For Oral Treprostinil. Reiterate OUTPERFORM & $91 FV.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 572

02/25/2013

Company Report

Pages: 11

Q4 Preview: We Believe Consensus Is Achievable, But Focus Is On March 31st PDUFA For Oral Treprostinil

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 573

02/14/2013

Daily Note

Pages: 7

Pulling A Rabbit Out Of Its Hat: FDA Accepts Rapid Resubmission Of Oral Treprostinil NDA With Class 1 Review And March 31 PDUFA

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 574

12/28/2012

Company Report

Pages: 7

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 575

11/25/2012

Daily Note

Pages: 10

While Growth And Valuation Remain Attractive

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 576

11/05/2012

Company Report

Pages: 8

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 577

11/01/2012

Company Report

Pages: 11

Q3 Revenues And Earnings Beat (Again) And We Project Consistent Double Digit Growth Through 2016. Reiterate OUTPERFORM and $91 Fair Value

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 578

10/29/2012

Company Report

Pages: 8

Price: 24.95

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 579

10/25/2012

Company Report

Pages: 11

Q3 Preview: We Believe Street Estimates Are Achievable;

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: United Therapeutics Corporation

Industry: Medical - Drugs

Record: 580

10/23/2012

Daily Note

Pages: 5

Oral Treprostinil Receives CRL Instead of Approval; We Recommend Buying On Weakness; Reiterate OUTPERFORM And $91 Fair Value

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party